These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25400826)

  • 1. ¹⁸F-fluorodeoxyglucose PET/CT features and correlations with histopathologic characteristics in sclerosing epithelioid fibrosarcoma.
    Luo Y; Hu W; Wu H; Xue H; Huo L; Li F; Zhao Y; Dai M
    Int J Clin Exp Pathol; 2014; 7(10):7278-85. PubMed ID: 25400826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
    Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
    Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT features of pulmonary sclerosing hemangioma.
    Lee E; Park CM; Kang KW; Goo JM; Kim MA; Paeng JC; Lee HJ; Park HS; Chung DH
    Acta Radiol; 2013 Feb; 54(1):24-9. PubMed ID: 22291338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
    Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
    HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
    Kim YI; Kim SK; Paeng JC; Lee HY
    Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A primary sclerosing epithelioid fibrosarcoma of the pubic bone, with evidence of divergent epithelial differentiation.
    Wang G; Eyden B
    Ultrastruct Pathol; 2010 Apr; 34(2):99-104. PubMed ID: 20192707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
    Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
    HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG-PET/CT in the assessment of pancreatic cancer: is the contrast or a better-designed trial needed?
    Nguyen NQ; Bartholomeusz DF
    J Gastroenterol Hepatol; 2011 Apr; 26(4):613-5. PubMed ID: 21418296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.